Previous Close | 0.5374 |
Open | 0.5462 |
Bid | 0.5050 x 1200 |
Ask | 0.5900 x 800 |
Day's Range | 0.5002 - 0.5893 |
52 Week Range | 0.4200 - 4.9150 |
Volume | |
Avg. Volume | 805,506 |
Market Cap | 60.211M |
Beta (5Y Monthly) | 1.23 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that the Company will participate in the following upcoming scientific and patient advocacy conferences: American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting – May 16-19, 2022, Washington, D.C.Carl Morris, Ph.D., Chief Scientific Officer at Solid Biosciences, will pr
- IGNITE DMD functional and durability patient data support advancement of SGT-001; Program transitioning to a commercially scaled transient transfection-based manufacturing process - - Novel capsid development to continue, supported by new preclinical data; Company anticipates early-2023 Investigational New Drug (IND) submission for SGT-003 for Duchenne - - Strategy and resource alignment support funding of operations through important clinical milestones and into Q2 2024 - - Solid Biosciences
CAMBRIDGE, Mass., April 25, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that it will release first quarter 2022 financial results before the market opens on Wednesday, April 27, 2022. Management will host a conference call on the same date beginning at 8:00 a.m. ET to discuss the Company’s financial results and a strategic update to develop SGT-001 and